Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.66 |
| ▸ | JAK1 | P23458 | 11/20 | 0.66 |
| ▸ | TYK2 | P29597 | 11/20 | 0.66 |
| ▸ | JAK3 | P52333 | 10/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13613453 | 0.81 | JAK2 (0.62) | JAK2JAK1TYK2JAK3HPGD | |
| SCHEMBL13613454 | 0.80 | JAK2 (0.54) | JAK2JAK1TYK2JAK3NPC1 | |
| SCHEMBL13606556 | 0.79 | JAK2 (1.00) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL13613448 | 0.77 | JAK2 (0.55) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL5458391 | 0.76 | JAK2 (0.75) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL13613447 | 0.76 | JAK2 (0.54) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL13606548 | 0.76 | JAK2 (0.68) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL4495900 | 0.74 | JAK2 (0.61) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL13606501 | 0.73 | JAK2 (0.65) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL13606546 | 0.73 | JAK2 (0.70) | JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155777-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | JAK2 1101/4885JAK1 1726/4885TYK2 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.